ICICI Securities has retained its Buy rating on Onesource Specialty Pharma with an unchanged target price of Rs 2400 following a visit to its drug-device combination plant in Bangalore, citing its G7 approvals for generic semaglutide, expanded DDC capacity to 700-950 litres and plans for further capacity additions, plus five new biologics partnerships.